Morgan Stanley
RGC icon

Morgan Stanley’s Regencell Bioscience RGC Stock Holding History

Morgan Stanley’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8K Sell
5,052
-15,026
-75% -$361K ﹤0.01% 6673
2026
Q1 		$511K Sell
20,078
-1,346
-6% -$38.1K ﹤0.01% 5474
2025
Q4 		$450K Sell
21,424
-16,418
-43% -$267K ﹤0.01% 5564
2025
Q3 		$585K Buy
37,842
+4,822
+15% +$69.2K ﹤0.01% 5440
2025
Q2 		$563K Buy
33,020
+32,830
+17,279% +$400K ﹤0.01% 5413
2025
Q1 		$159 Sell
190
-79,610
-100% -$22K ﹤0.01% 7499
2024
Q4 		$10.4K Buy
+79,800
New +$12K ﹤0.01% 6787
2023
Q4 		– Sell
-12,388
Closed -$4.56K – 7893
2023
Q3 		$4.56K Buy
12,388
+950
+8% +$395 ﹤0.01% 6936
2023
Q2 		$6.53K Buy
11,438
+152
+1% +$102 ﹤0.01% 6923
2023
Q1 		$7.69K Buy
11,286
+608
+6% +$448 ﹤0.01% 6959
2022
Q4 		$7.64K Buy
10,678
+2,052
+24% +$1.57K ﹤0.01% 7029
2022
Q3 		$7K Buy
8,626
+2,964
+52% +$2.6K ﹤0.01% 7186
2022
Q2 		$5K Buy
5,662
+5,434
+2,383% +$4.1K ﹤0.01% 7406
2022
Q1 		$0 Buy
+228
New +$195 ﹤0.01% 8089
2021
Q4 		– Sell
-19,114
Closed -$11K – 8088
2021
Q3 		$11K Buy
+19,114
New +$8.62K ﹤0.01% 7291

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Morgan Stanley's RGC Position: Q2 2026 in Review

Morgan Stanley reduced its Regencell Bioscience (RGC) stake by 75% in Q2 2026, selling an estimated $361K and leaving 5,052 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6673.

Morgan Stanley first reported a position in RGC in Q3 2021 and has held it in 15 quarters since. The position peaked at $585K in Q3 2025. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Morgan Stanley held 5,052 shares of Regencell Bioscience worth $30.8K as of Q2 2026.
  • Morgan Stanley sold 15,026 Regencell Bioscience shares in Q2 2026, an estimated $361K.
  • Regencell Bioscience made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6673 holding.
  • Morgan Stanley first reported a position in Regencell Bioscience in Q3 2021 and has held it in 15 quarters since.
  • Morgan Stanley's Regencell Bioscience position peaked at $585K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.